Results 351 to 360 of about 3,691,311 (372)
Some of the next articles are maybe not open access.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
The Lancet, 1998 W. Hacke, M. Kaste, C. Fieschi, R. Kummer, A. Dávalos, Dieter Meier, V. Larrue, E. Bluhmki, S. Davis, G. Donnan, D. Schneider, E. Díez-Tejedor, P. Trouillas +12 moresemanticscholar +1 more sourceAdjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
The Lancet Oncology, 2015 J. Bruix, T. Takayama, V. Mazzaferro, G. Chau, Jiamei Yang, M. Kudo, J. Cai, R. Poon, K. Han, W. Tak, H. Lee, T. Song, S. Roayaie, L. Bolondi, K. Lee, M. Makuuchi, F. Souza, M. Berre, G. Meinhardt, J. Llovet +19 moresemanticscholar +1 more sourceDirectional DBS increases side‐effect thresholds—A prospective, double‐blind trial
Movement Disorders, 2017 T. Dembek, P. Reker, V. Visser-Vandewalle, J. Wirths, H. Treuer, M. Klehr, J. Roediger, H. Dafsari, M. Barbe, L. Timmermann +9 moresemanticscholar +1 more sourceBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
The Lancet, 2007 B. Escudier, A. Płużańska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, Marek Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J. Bay, I. Bodrogi, A. Jagiełło-Gruszfeld, N. Moore +14 moresemanticscholar +1 more sourceRandomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
The Lancet, 1997 J. Staessen, R. Fagard, L. Thijs, H. Celis, G. Arabidze, W. Birkenhäger, C. Bulpitt, P. W. Leeuw, C. Dollery, A. Fletcher, F. Forette, G. Leonetti, C. Nachev, E. Brien, J. Rosenfeld, J. Rodicio, J. Tuomilehto, A. Zanchetti +17 moresemanticscholar +1 more source